TD Cowen analyst Marc Frahm has maintained their bullish stance on AGIO stock, giving a Buy rating on February 11.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Marc Frahm has given his Buy rating due to a combination of factors regarding Agios Pharma’s prospects. The company’s recent financial results show promise, with Q4 Pyrkynd revenue exceeding expectations. Furthermore, the completion of Phase III RISE UP enrollment and the anticipated data for late 2025 indicate potential growth and developments in their pipeline.
Additionally, Agios is progressing with its mitapivat sNDA, which is under review by the FDA, and has significant sales potential given its applications in thalassemia and sickle cell disease. The company’s strategic moves to expand its market reach, including regulatory filings in the EU, Saudi Arabia, and UAE, and preparation for a commercial launch, position it well for future success. The proactive efforts in building a sales force and commercial infrastructure further support the positive outlook for Agios Pharma’s stock.
In another report released on February 11, Bank of America Securities also reiterated a Buy rating on the stock with a $54.00 price target.